Ripretinib is a Small Molecule owned by Deciphera Pharmaceuticals, and is involved in 10 clinical trials, which were completed.
Ripretinib (Qinlock, DCC-2618) blocks cKIT mutated in a region called (exon 17) and the mutant D816V form of cKIT causative of mast cell leukemia and mastocytosis. The proto-oncogene c-Kit forms an active dimer that autophosphorylates itself and activates a signaling cascade that induces cell growth. PDGF and its receptors are implicated in tumorigenesis and angiogenesis. Thus, DCC-2618 acts on a mutant cKIT and mutant platelet derived growth factor receptor (PDGFR) alpha and inhibits tumor cell proliferation and angiogenesis.
The revenue for Ripretinib is expected to reach a total of $632m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Ripretinib NPV Report.
Ripretinib (Qinlock) is a potent antineoplastic agent. It is formulated as tablets for oral route of administration. Qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.
Ripretinib (DCC-2618) was under development for the treatment of gastrointestinal stromal tumor (GIST), melanoma, anaplastic astrocytomas, glioblastoma multiforme, non-small cell lung cancer, glioma, germ cell tumors, penile cancer, soft tissue sarcoma, hematologic malignancy, systemic mastocytosis, solid tumor and mast cell leukemia. The drug candidate is a small molecule, administered through the oral route. It binds to mutant cKIT (including exons 14 and 17) and mutant platelet derived growth factor receptor alpha (PDGFRA). It is developed based on kinase inhibitor technology platform which provides the basis for the discovery and development of kinase switch pocket inhibitors.
Zai Lab Overview
Zai Lab biopharmaceutical company that carries out drug development, discovery and commercializing therapies which address medical conditions with unmet needs in oncology. The company offering products pipeline includes Zejula Niraparib is a once-daily small molecule poly (ADP-ribose) polymerase 1/2inhibitor, Optune Tumor Treating Fields for cancer treatment, Qinlock Ripretinib and NUZYRA Omadacycline, a novel tetracycline-class antibacterial. The company market its products to the United States, Europe, Canada, Australia, Greater China and certain other countries and regions. Zai Lab is headquartered in Shanghai, China.
The company reported revenues of (US Dollars) US$144.3 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$49 million in FY2020. The operating loss of the company was US$700.1 million in FY2021, compared to an operating loss of US$301.8 million in FY2020. The net loss of the company was US$704.5 million in FY2021, compared to a net loss of US$268.9 million in FY2020. The company reported revenues of US$57.5 million for the third quarter ended September 2022, an increase of 19.4% over the previous quarter.
Quick View – Ripretinib
|Highest Development Stage|